M-100 continuous hemodialysis filtration medium for removing inflammatory mediators in patients with multiple organ dysfunction syndrome(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2017年第11期
- Page:
- 1160-1166
- Research Field:
- 医学信号处理与医学仪器
- Publishing date:
Info
- Title:
- M-100 continuous hemodialysis filtration medium for removing inflammatory mediators in patients with multiple organ dysfunction syndrome
- Author(s):
- ZHANG Lei; LIANG Xinhua; MO Ying; MAIMAITI Buheliqi; ZHANG Cuiping; BI Xueying
- Department of Nephropathy, the Fifth Affiliated Hospital of Xinjiang Medical University, Urumchi 830011, China
- Keywords:
- ; Keywords: continuous veno-venous hemodifiltration; multiple organ dysfunction syndrome; systemic inflammatory response syndrome; inflammation mediator
- PACS:
- R318；R692.5
- DOI:
- DOI:10.3969/j.issn.1005-202X.2017.11.015
- Abstract:
- Abstract: Objective To explorethe effect of continuous veno-venous hemodifiltration (CVVHDF) using M-100 continuous hemodialysis filtration medium for clearance of inflammatory mediators in patients with multiple organ dysfunction syndrome (MODS) and for improving the clinical symptoms and prognosis of the patients. Methods Between September, 2014 and December, 2015, 40 patients who met the diagnostic criteria of MODS, systemic inflammatory response syndrome (SIRS) or sepsis were admitted in the Fifth Affiliated Hospital of Xinjiang Medical University. The patients were divided into treatment group (n=22) and control group (n=18) to receive routine medical treatment combined with CVVHDF and routine medical treatment alone for more than 3 days, respectively. In the first 3 days of treatment, the changes in serum concentrations of inflammation mediators were analyzed, and the levels of tumor necrosis factor (TNF)-α, interleukin-6 (IL-6) and IL-10 were determined with ELISA; the vital signs, BUN and Cr levels of the patients were also recorded. The total hospital stay and survival rate of patients were analyzed. Results Sixteen (72.73%) patients in the treatment group survived as compared with only 7 (38.89%) in the control group (P<0.05). The total hospital stay was significantly shorter in the treatment group than in the control group ［(14.60±4.12) d vs (18.20±4.51) d, P<0.05］. After the treatment, the patients in the treatment group showed significantly lower TNF-α, IL-6, and IL-10 levels (P<0.05) and presented with more obvious improvements in APACHE II score, BUN, Cr level, mean arterial pressure, heart rate, and oxygen saturation (P<0.05) than those in the control group. Conclusion CVVHDF can effectively remove inflammatory mediators in patients with MODS and improve the clinical symptoms and prognosis of the patients.
Last Update: 2017-11-23